SCHEMBL24714737

SCHEMBL24714737

COc1cc2ncnc(Nc3cc(-c4ccco4)ccc3OC)c2cc1NC(=O)/C=C/CN1CCN(C)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.57
ERBB2 P04626 16/20 0.57
ERBB4 Q15303 12/20 0.57
JAK3 P52333 4/20 0.57
GAK O14976 1/20 0.55
RIPK2 O43353 1/20 0.55
NR1I2 O75469 1/20 0.55
LCK P06239 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
CHRM1 P11229 1/20 0.55
SRC P12931 1/20 0.55
DRD2 P14416 1/20 0.55
ADRA2C P18825 1/20 0.55
SLC6A2 P23975 1/20 0.55
MC3R P41968 1/20 0.55
SLC6A3 Q01959 1/20 0.55
PDE4D Q08499 1/20 0.55
KCNH2 Q12809 1/20 0.55
RIPK3 Q9Y572 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24714928 0.93 EGFR (0.57) EGFRERBB2ERBB4JAK3GAK
SCHEMBL30820505 0.87 EGFR (0.48) EGFRERBB2ERBB4JAK3GAK
SCHEMBL27150020 0.87 EGFR (0.48) EGFRERBB2ERBB4JAK3GAK
SCHEMBL24713924 0.86 EGFR (0.49) EGFRERBB2ERBB4JAK3GAK
SCHEMBL30822058 0.86 EGFR (0.49) EGFRERBB2ERBB4JAK3GAK
SCHEMBL27139095 0.84 EGFR (0.60) EGFRERBB2ERBB4JAK3GAK
SCHEMBL24714632 0.83 EGFR (0.56) EGFRERBB2ERBB4JAK3
SCHEMBL30822063 0.83 EGFR (0.56) EGFRERBB2ERBB4JAK3
SCHEMBL27145363 0.83 EGFR (0.56) EGFRERBB2ERBB4JAK3
SCHEMBL30822096 0.83 EGFR (0.57) EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4328222-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-02-28 EP claimed
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC. (KR) 2024-07-25 US disclosed
EP-4328222-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-02-28 EP disclosed
EP-4328222-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-02-28 EP disclosed
WO-2022225238-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 보로노이 주식회사 2022-10-27 WO disclosed
WO-2022225238-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 보로노이 주식회사 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF ERBB2, EGFR, ERBB3 EGFR 2/4885ERBB2 1/4885ERBB4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.